A detailed history of Exodus Point Capital Management, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 69,282 shares of PHAT stock, worth $527,236. This represents 0.01% of its overall portfolio holdings.

Number of Shares
69,282
Holding current value
$527,236
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.25 - $19.5 $710,140 - $1.35 Million
69,282 New
69,282 $1.25 Million
Q3 2023

Nov 09, 2023

BUY
$10.26 - $15.7 $174,502 - $267,025
17,008 New
17,008 $176,000
Q2 2021

Aug 16, 2021

SELL
$32.66 - $39.87 $246,060 - $300,380
-7,534 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$33.86 - $48.68 $255,101 - $366,755
7,534 New
7,534 $283,000
Q2 2020

Aug 14, 2020

SELL
$25.06 - $54.6 $470,250 - $1.02 Million
-18,765 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$24.65 - $42.83 $462,557 - $803,704
18,765 New
18,765 $485,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $298M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.